Home

The main activities of the "PharmaDiall" company are search, development, chemical synthesis, "in vitro" and "in vivo" testing, organization and performing the clinical trials (all phases) and patenting of new biologically active chemicals that can later turn into drugs.

News

01.04.2021, a visit was made to the SPC Pharmzaschita

01.04.2021, a visit was made to the SPC Pharmzaschita
On 01.04.2021, a visit was made to the SPC Pharmzaschita in order to get acquainted with the new capabilities of the production partner of LLC "PharmaDiall" for the production of API and FFF. The equipment put into operation at the end of 2020 was shown. PharmaDiall CEO Oleg E. Balashov and COO Dmitry G. Tovbin were satisfied with what they saw.

23.02.2021 new article published in Curr Drug Discov Technol.

23.02.2021 new article published in Curr Drug Discov Technol.

Dmitry G. Tovbin, Dmitry N. Tarasov, Dmitry V. Malakhov, Natalia A. Tserkovnikova, Arseniy V. Aybush, Natalia N. Drozd

Curr Drug Discov Technol. 2021 Feb 23.
The Development of New Low-Molecular-Weight Factor Xa Inhibitors That Are Potential Anticoagulants

DOI: 10.2174/1568009621666210224104940